Advanced Medical Solutions Group plc

("AMS", the "Company" or the "Group")

            Director/PDMR and PCA Shareholding

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that it was notified on 24 September 2025 that on the same day Chris Meredith, who is a Director and PDMR, transferred, through sale and repurchase, a total of 50,510 Ordinary Shares of 5p held on his behalf held in the name of Platform Securities Nominees Limited ("Nominee"), at a sale price of 218.5p per Ordinary Share to (i) a combination of Individual Savings Accounts ("ISA's") and Self-Invested Personal Pensions (SIPP's) held in the name of Chris Meredith and Ingrid Meredith; and (ii) his adult Children, all at a price of 218.54p per Ordinary Share.

The number of shares, and the beneficial ownership of the shares, held by Chris Meredith, Ingrid Meredith and his PCA's remains unchanged. These transactions are part of normalised tax planning.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

- End -

For further information, please visit www.admedsol.com or contact:

About Advanced Medical Solutions Group plc - see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand^®, RESORBA^®, LiquiBandFix8^®, LIQUIFIX™, Peters Surgical, Ifabond, Vitalitec and Seal-G^®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal^® brand as well as under white label. Since 2019, the Group has made seven acquisitions: Sealantis, an Israeli developer of innovative internal sealants, Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business, Connexicon, an Irish tissue adhesives specialist, Syntacoll, a German specialist in collagen-based absorbable surgical implants and Peters Surgical, a global provider of specialty surgical sutures, mechanical haemostasis and internal cyanoacrylate devices.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, Thailand, India, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, France, Poland, Benelux, India, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 1,600 employee For more information, please see www.admedsol.com.